INTRODUCTION AND OBJECTIVES: A good pelvic lymph node dissection (PLND) during radical cystectomy (RC) is a standard of practice. Although the extent of PLND is debatable, the progressionfree survival and overall survival have been correlated with the number of nodes removed during surgery. The sentinel marker of lymph node dissection which is the lymph node density (LNd) is not used in routine practice as a prognostic variable.
OBJECTIVE: To evaluate the prognostic value of LNd in Ca Bladder and to evaluate a cut off value of LNd that correlates with prognosis and survival for patients undergoing RCþPLND.
METHODS: The records of patients undergoing upfront RC þ PLND over consecutive five years in a cancer institute, were analysed retrospectively excluding those who received neoadjuvant chemotherapy or treatment failures following bladder conservation therapy.
RESULTS: A total of 152 patients were analysed (M:F 139:13) with median age of 62 years. 76 (50.7%) were found to have nodal metastasis out of which 34 were found to have perinodal extension. 59 (77.6%) received adjuvant chemotherapy and 16 (21.1%) received postoperative radiotherapy. One patient was given postoperative chemo-radiation. At median follow up of 60 months, 47 of the 150 patients had died of the disease. The median lymph nodes yield was 17 (6-36). On univariate analysis number of lymph nodes dissected did not correlate with survival. However pT stage, presence of perinodal extension and LNd were all found to affect survival significantly in both univariate and multivariate analysis with a hazard ratio of 3.23 for perinodal extension. LNd of less than 10% did not correlate with survival but a range between 10-20% and > 20% showed a hazard ratio of 3.9 and 6.6 respectively. The mean survival for patients with node negative disease was 109 months which reduced to 24 months amongst patients with LNd of > 0.21. LNd cutoff value of 15% was found to be most relevant and applicable for survival.
CONCLUSIONS: Lymph node density is the one of strongest predictor of overall survival in urinary bladder cancer. A proposed lymph node density threshold of 15% correlates well with recurrence and survival and for prognostication.
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PD57-04 MOLECULAR PREDICTORS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND PROGNOSIS IN MUSCLE-INVASIVE BLADDER CANCER
Mauro Ragonese*, Luca Di Gianfrancesco, Giovanni Schinzari, Giuseppe Palermo, Marco Racioppi, PierFrancesco Bassi, Rome, Italy INTRODUCTION AND OBJECTIVES: Multiple molecular biomarkers have been proposed as predictors of neoadjuvant chemotherapy efficacy in urothelial muscle-invasive bladder cancer. Despite emerging evidences, these data are not yet translated into clinical practice. Our study evaluates the prognostic and predictive role of the expression of the human equilibrative nucleoside transporter 1 (hENT1) and the excision repair cross complementing 1 (ERCC1) in bladder cancer receiving neoadjuvant chemotherapy with gemcitabine and platinum derivatives.
METHODS: Clinical records of forty patients with muscleinvasive bladder cancer who received neoadjuvant gemcitabineplatinum combination chemotherapy were retrospectively analyzed. The primary endpoint was histopathologic complete response (pCR) rate and the secondary endpoints were disease-free survival (DFS) and overall survival (OS). Clinical and histopathologic parameters along with ERCC1 and hENT1 expression, assessed by RT-PCR in chemo-naive primary bladder tumor specimen, were examined and correlated with pCR rates, DFS and OS. To test the hypothesis that patients with hENT1þve and low ERCC1 level tumors had better outcomes, an exploratory analysis of pCR rate was performed in two prognostic subgroups: subgroup A, containing hENT1þve and low ERCC1 level population; subgroup B, containing hENT1-ve and high ERCC1 level population plus patients having both expressions of hENT1 and ERCC1 with same tendency.
RESULTS: pCR rate in the whole population was 40% (16 out of 40 patients), while in hENT1þve and low ERCC1 level population (subgroup A) was 61.5% (16 out of 26 patients) which was signicantly higher than in patients with either both expressions of biomarerks with
